RBT Biotech Company (BioTechnology Developments) and the Skolkovo Foundation have entered into an agreement to reimburse the costs to individuals investing in RBT’s developments.
RBT is conducting a private offering on the Rounds investment platform. Investments will be used to expand the portfolio of vaccines developed by the company and to complete clinical trials of the influenza vaccine. The underwriter of the offering is also the Alfa Investments service.
For individual investors, commonly referred to as business angels, the Skolkovo Foundation can reimburse up to 50% of the amount invested in RBT, but not more than the personal income tax paid by the investor for the three previous years. For this reimbursement, every private investor must invest at least RUB 1 million.
According to the Chairman of the Board of Directors of HSCI Artur Isaev: “In economies that are actively developing innovations in biotech and other areas, one of the means to promote investments is tax refund. The idea is that the government invests together with effective business angels, partially refunding the taxes investors paid to the budget. Availability of such an investment support tool in Skolkovo is an important step towards the development of the country’s innovation ecosystem.”
RBT is a company of the Human Stem Cell Institute group (HSCI, MOEX: ISKJ), a resident of Skolkovo and Medtech Moscow, the Moscow Center for Innovative Technologies in Healthcare Technopark.
Together with HSCI, RBT is developing a platform for the development of candidate antiviral vaccines based on surface recombinant proteins and spherical adjuvant particles. Previously, this platform was used to develop coronavirus vaccine Betuvax-Cov-2 and influenza vaccine TetraFluBET, as well as a pentavalent combination vaccine against influenza and coronavirus developed jointly with the Nacimbio pharmaceutical holding. RBT’s technology platform is aimed at making vaccines less reactogenic and minimizing their side effects, while maintaining the “protective” properties of vaccines, such as immunogenicity, at a high level. The company’s pipeline also includes a human papillomavirus vaccine.
For the investment procedure, please visit: https://rbiotech.ru/invest-rbt